Wenz F, Lohr F, Flentje M, Rudat V, Dietz A, Wannenmacher M
Department of Clinical Radiology, University of Heidelberg, Germany.
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):771-6. doi: 10.1016/s0360-3016(97)00024-2.
Proliferation of tumor cells during radiotherapy may limit tumor control, especially in rapidly proliferating tumors such as head and neck carcinomas. We present a flow cytometric method for detection of PCNA in solid head and neck tumors and how these data correlate with outcome.
Pretherapeutic biopsies of 20 inoperable patients with Stage IV squamous cell carcinoma were examined. Biparametric flow cytometry was done after anti-PCNA (PC10) and propidium iodine staining were performed. PCNA index (percentage PCNA positive cells), DNA index, and S phase fraction (SPF, euploid tumors only) were determined. The therapy consisted of an accelerated-hyperfractionated radiochemotherapy (66 Gy/5 weeks, concomitant boost of 1.6 Gy/day in weeks 4+5, Carboplatin 5 x 70 mg/m2 in weeks 1+5). The median follow-up time was 30 months.
Fourteen patients suffered from disease progession and 12 died. Median actuarial, cause-specific survival, and disease-free survival (DFS) times were 17 and 9 months, respectively. PCNA indices ranged from 4 to 70% (median 9%); there were 7 aneuploid and 13 euploid tumors. SPF ranged from 4 to 14.5% (median 10.5%). Neither SPF nor ploidy had a significant influence on outcome. Patients were divided according to PCNA index in higher (n = 10) and lower (n = 10) than the median. Survival and DFS were 13 and 6 months for the group >9% and 20 and 15 months for the group <9%. The difference in DFS was significant (p = 0.03, log rank test).
These results fall in line with other studies showing the influence of pretherapeutic proliferation on outcome after radiotherapy. Although the moderately accelerated therapy regimen certainly reduces the influence of proliferation on outcome, patients with faster proliferating tumors still have a worse outcome. DFS is the more relevant endpoint in this study because of effective salvage therapies, which influence survival.
放疗期间肿瘤细胞的增殖可能会限制肿瘤控制,尤其是在头颈部癌等快速增殖的肿瘤中。我们提出一种流式细胞术方法来检测头颈部实体肿瘤中的增殖细胞核抗原(PCNA),以及这些数据与预后的相关性。
对20例无法手术的IV期鳞状细胞癌患者进行治疗前活检。在进行抗PCNA(PC10)和碘化丙啶染色后进行双参数流式细胞术检测。确定PCNA指数(PCNA阳性细胞百分比)、DNA指数和S期分数(仅适用于整倍体肿瘤)。治疗方案为加速超分割放化疗(66 Gy/5周,第4周和第5周每天同步推量1.6 Gy,第1周和第5周卡铂5×70 mg/m²)。中位随访时间为30个月。
14例患者病情进展,12例死亡。中位精算生存率、病因特异性生存率和无病生存率(DFS)分别为17个月和9个月。PCNA指数范围为4%至70%(中位值9%);有7例非整倍体肿瘤和13例整倍体肿瘤。S期分数范围为4%至14.5%(中位值10.5%)。S期分数和倍性均对预后无显著影响。根据PCNA指数将患者分为高于中位数组(n = 10)和低于中位数组(n = 10)。PCNA指数>9%组的生存率和DFS分别为13个月和6个月,PCNA指数<9%组分别为2个月和15个月。DFS的差异具有显著性(p = 0.03,对数秩检验)。
这些结果与其他研究一致,表明治疗前增殖对放疗后预后有影响。尽管中度加速治疗方案肯定会降低增殖对预后的影响,但肿瘤增殖较快的患者预后仍然较差。由于有效的挽救治疗会影响生存,DFS是本研究中更相关的终点。